OS Therapies names Kerry Clem chief commercial officer

• OS Therapies named Kerry Clem chief commercial officer to lead launch planning for Herlystic across the U.S., U.K., Europe.
• Clem previously served as CEO of Solaxa, chief commercial officer at Acorda Therapeutics, held commercial leadership roles at Allos Therapeutics.
• Frank Knuettel II was appointed chief financial officer as the company prepares to transition toward commercialization.
• Knuettel most recently served as CFO of Pelthos Therapeutics, previously CEO of Channel Therapeutics, led more than 15 M&A deals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-106849), on October 05, 2026, and is solely responsible for the information contained therein.